AzTrials
AzTrials

Post-Spinal ShiveringPhase 4OOPSNCT07088601

Efficacy of Oral Ondansetron Strips on Prevention of Post-Spinal Shivering

A Phase 4 study testing Oral ondansetron strips in people with Post-Spinal Shivering, run by Cairo University.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record
Search all trials

Trial summary

This study aims to investigate the efficacy of oral ondansetron film strips on the incidence of post-spinal shivering in patients undergoing surgeries using spinal anesthesia at Kasr Alainy hospitals, Cairo University. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Post-Spinal Shivering
What is being tested?
Oral ondansetron strips
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
50 participants
Where
No sites listed yet
Study dates
10 Aug 2025to 29 Dec 2025
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • American Society of Anesthesiologists (ASA) physical status I, II.
  • Patients underwent elective surgical procedures under spinal anesthesia in the lower half of the body such as orthopedic, urological, or general surgeries.

Who cannot join

  • Patient refusal.
  • Morbid obese patients or those who were not candidates for spinal anesthesia.
  • Pregnant females.
  • Patients with comorbidities such as severe cardiopulmonary, severe hepatic or renal diseases, thyroid disorders, and convulsions.
  • Uncooperative patients and patients with psychological disorders.
  • Patients on regular ondansetron or other antiemetics.
Show all 10Show fewer
  • Patients taking selective serotonin reuptake inhibitors.
  • Patients with allergy to 5-HT3 receptor antagonist drugs.
  • Patients receiving saddle spinal block.
  • In surgeries less than 1 h or longer than 3 hours duration.

About this study

Official title: Efficacy of Oral Ondansetron Strips on Prevention of Post-Spinal Shivering; a Double Blinded, Randomized Controlled Study

This study aims to investigate the efficacy of oral ondansetron film strips on the incidence of post-spinal shivering in patients undergoing surgeries using spinal anesthesia at Kasr Alainy hospitals, Cairo University.

This prospective, double-blinded, randomized controlled study will be conducted on 50 patients aged from 18 to 65 years of both sexes with ASA I, II who are scheduled for elective surgical procedures under spinal anesthesia in the lower half of the body such as orthopedic, urological, or general surgeries. Patients will be divided into two equal groups: Group (O) will receive oral ondansetron in the form of an oral soluble film 4 mg strip immediately before insertion of IV cannula and group (C) will receive a placebo in the form of an oral peppermint strip immediately before insertion of the IV cannula.

Read the detailed description

In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group O will receive oral ondansetron in the form of an oral soluble film 4 mg strip (Ondalenz, 4 mg orodispersible films of Nerhadou International Co.) and patients in group C will receive a placebo in the form of an oral peppermint strip (Listerine Cool Mint Pocketpakas).

Following the insertion of a cannula; IV midazolam at a dose of 0.05 mg/kg will be administered intravenously. Then the patient will be transferred immediately to the operating theatre.

On entering the operating room; all patients will be connected to standard ASA monitoring which included electrocardiography (ECG), non-invasive arterial blood pressure (NIBP) including systolic, diastolic, mean arterial blood pressure (MAP) and Oxygen saturation using pulse oximetry.

With the patient sitting on the operating table, the L3-L4 interspace will be identified by identification of Tuffier's line. Under complete aseptic conditions, a dural puncture will be achieved by a 22G pencil-point spinal needle that will be introduced in a paramedian (lateral) approach through the L3-4 intervertebral space. After CSF aspiration and confirmation of correct intrathecal space, 3.5 mL of Sunny Pivacaine 0.5% (hyperbaric bupivacaine 20mg/4mL amp of Sunny pharmaceutical group) plus 25 μg of fentanyl-Hameln (of Sunny pharmaceutical group) will be injected over one minute.

The sensory block will be assessed by a pinprick test and the motor block will be assessed using a modified Bromage scale (0 = no motor block; 1= hip is blocked; 2= hip and knee are blocked; 3= hip, knee, and ankle are blocked). Peak sensory level will be confirmed and if a sensory level < T8 the patient will be excluded. If general anesthesia is needed for any reason, the patient will also be excluded from the study.

The ambient room temperature will be maintained at 24°C. IV fluids will be administered according to the conventional way as follows, hourly maintenance was the sum of A (4x first 10 Kg body weight), B (2x next 10 Kg body weight) and C (1x remaining Kg bodyweight) in addition to deficit (or fasting requirements), that will be hourly maintenance multiplied by the numbers of hours of fasting, half of it will be administered in the first hour and the second half will bne administered during second and third hours of surgery. Balanced crystalloids such as Ringer's lactate or acetate will be preferred over normal saline. Blood loss will be estimated through the surgical field, towels, gauzes and suction jar \& will be replaced by crystalloids 1:3 or colloid/blood and blood products 1:1 ratio. All IV fluids will be administered at room temperature. All patients will be covered with surgical drapes from the lower extremities up to the lower chest during the operation. No warming devices will be used. Supplementary oxygen by a face mask will be given to all patients at a rate of 6 L/min.

The tympanic temperature will be monitored and measured by using the Braun ThermoScan 5 Ear Thermometer model IRT 6500. Hypothermia will be defined as a tympanic membrane temperature < 36.5◦ C.

Shivering score will then be assessed according to the Bedside shivering assessment score (BSAS) . If shivering scores ≥ 3, 30 mg of IV pethidine were administered as a rescue dose.

Postoperative:

Patients will be discharged to post anesthesia care unit (PACU). All patients will be monitored in the post-anesthesia care unit (PACU), covered by one cotton blanket over their entire body. The PACU temperature will be maintained at 24ºC.

The adverse effects will be assessed: allergic reaction from the used drugs, complications from the surgery done as:

Hypotension (MAP < 20% of baseline). In case of hypotension, the patients will be managed with intravenous loading with Ringer's lactate and boluses of 10 mg ephedrine IV.

Bradycardia (HR< 60 beats/min). In the case of bradycardia, the patients will be managed with 0.02 mg/kg atropine IV.

Respiratory depression will be considered if the respiratory rate is less than 10 breaths per minute and oxygen saturation (SpO2) was < 92% for 30 or more seconds.

Being tested
Oral ondansetron strips, Placebo (oral peppermint strip)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Oral ondansetron stripsDrug

    In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group O will receive oral ondansetron in the form of an oral soluble film 4 mg strip.

  • Placebo (oral peppermint strip)Other

    In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group C will receive a placebo in the form of an oral peppermint strip.

Study groups in NCT07088601
Study groupRoleWhat they receive
Group OActive comparatorPatients will receive oral ondansetron in the form of an oral soluble film 4 mg strip.
Receives: Drug: Oral ondansetron strips
Group CPlacebo comparatorPatients will receive a placebo in the form of an oral peppermint strip
Receives: Other: Placebo (oral peppermint strip)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The incidence of shivering.

    It is defined by the highest shivering score ≥ 3 at any time starting from 15 min after lumber puncture until 180 min following it.

    Measured: starting from 15 minutes after lumber puncture until 180 minutes following it and postoperative.

Secondary outcomes (7)
  1. The onset time of significant shivering

    Time in min from the onset of significant shivering ≥ 3 on shivering score

    Measured: started from 15 minutes after lumbar injection until 180 minutes following lumbar injection and postoperative

  2. Incidence of hypothermia

    Core body temperature will be measured by ear thermometer immediately before lumbar puncture (base level), and then at 15-minute intervals until 180 min after lumbar puncture and postoperative. Hypothermia will be defined as a tympanic membrane temperature < 36.5◦ C.

    Measured: started from 15 minutes after lumbar injection until 180 minutes after lumbar injection and postoperative.

  3. The shivering score

    Shivering score will be assessed according to the Bedside shivering assessment score (BSAS) as: Grade I: Mild fasciculation of face, neck, or head, or peripheral vasoconstriction, Grade II: Visible tremor involving one muscle group, Grade III Muscular activity in more than one muscle group but not generalized, and Grade IV: Gross muscular activity involving the entire body. The minimum is grade I and the maximum is Grade IV. Higher grades mean increased severity.

    Measured: will be assessed at 15 minutes intervals during the operation and in the recovery room started from 15 minutes after the lumbar puncture until 180 minutes after the lumbar puncture and postoperative.

  4. Incidence of patients given pethidine

    If shivering scores ≥ 3, 30 mg of IV pethidine will be administered as a rescue dose.

    Measured: started from 15 minutes after the lumbar puncture until 180 minutes after the lumbar puncture and postoperativde.

  5. Correlation between the incidence of shivering score ≥ 3 and hypothermia.

    Correlation between the incidence of shivering score ≥ 3 as measured by Bedside Shivering Assessment Score (BSAS) and hypothermia as measured by tympanic thermometer (<36.5).

    Measured: started 15 minutes after lumbar puncture until 180 minutes after lumbar puncture and postoperatively

  6. The incidence of adverse effects

    e.g., hypotension, arrhythmias as bradycardia, nausea, vomiting, headache, itching, hypoxemia, and total spinal block) will be detected and recorded

    Measured: started 15 minutes after lumbar puncture until 180 minutes after lumbar puncture and postoperatively

  7. Correlation between the incidences of postoperative nausea, vomiting, and shivering

    Measured: started 15 minutes after lumbar puncture until 180 minutes after lumbar puncture and postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jul 2025
  2. Study start10 Aug 2025 (estimated)
  3. Primary completion29 Dec 2025 (estimated)
  4. Study completion29 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07088601
Sponsor's protocol ID
MS-442-2024
Acronym
OOPS
Status last verified
Dec 2024
First submitted
19 Jul 2025
Last updated
30 Jul 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Oral ondansetron strips in people with Post-Spinal Shivering, run by Cairo University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 30 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The incidence of shivering. (time frame: starting from 15 minutes after lumber puncture until 180 minutes following it and postoperative.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in